AS Bravo Pharmaceuticals

Active Registry code 14159974 AS Haabneeme alevik Registered 29 Nov 2016

AS Bravo Pharmaceuticals is a AS based in Haabneeme alevik, registry code 14159974, status: active. Main activity: Other human health activities n.e.c.. According to EMTA, turnover for Q3 2026 was €0 with 2 employees.

Turnover

0 €

State taxes

877 €

↑ 0.0% vs Q2 2026

Labour taxes

923 €

↑ 0.0% vs Q2 2026

Employees

±0 vs Q2 2026

Q3 2026 · data from the Tax and Customs Board (EMTA)

Position in the industry Human health activities · EMTAK 86

Labour taxes per employee 462 €

above 10% of companies

industry median 2 177 € · companies in the industry: 1 696
Revenue · 2024 28 873 €

above 55% of companies

industry median 20 000 € · companies in the industry: 3 347
Net profit margin · 2024 -246.5 %

above 2% of companies

industry median 10.7 % · companies in the industry: 2 757

Taxes and turnover

Q4 2023 – Q3 2026

Turnover, € Q3 2026: 0 € · industry median 9 428 € · above 2% of the industry

Company
Industry median

Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Labour taxes per employee, € Q3 2026: 462 € · +0.0% vs Q2 2026 · industry median 2 177 € · above 10% of the industry

Company
Industry median

Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Employees Q3 2026: 2 · +0.0% vs Q2 2026

State taxes, € Q3 2026: 877 € · +0.0% vs Q2 2026

Figures by quarter
Quarter	Turnover, €	State taxes, €	Labour taxes, €	Employees
Q3 2026	—	877	923	2
Q2 2026	—	877	923	2
Q1 2026	—	3 042	2 826	2
Q4 2025	—	—	—	1
Q3 2025	—	1 743	1 651	1
Q2 2025	—	6 288	5 656	1
Q1 2025	3 443	4 324	2 901	1
Q4 2024	5 421	4 683	4 025	1
Q3 2024	—	5 223	4 571	1
Q2 2024	17 100	7 415	4 844	1
Q1 2024	10 674	7 013	4 791	1
Q4 2023	14 557	7 123	4 685	1
Q3 2023	—	6 808	5 697	1
Q2 2023	—	4 141	3 637	1
Q1 2023	—	5 485	4 591	1
Q4 2022	—	5 519	4 614	1
Q3 2022	—	5 376	4 574	1
Q2 2022	4 000	5 377	4 574	1
Q1 2022	15 775	5 453	4 574	1

Labour taxes per employee per month

154 €

Turnover per employee in the quarter

0 €

Q3 2026 · calculated from EMTA data

Financials by year

2017 – 2024

Revenue, € 2024: 28 873 € · +44.8% vs 2023 · industry median 20 000 € · above 55% of the industry

Company
Industry median

Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit, € thousand 2024: -71 167 € · +16.5% vs 2023 · industry median 1 621 € · above 2% of the industry

Company
Industry median

Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit margin, % 2024: -246.5 % · +180.8 pp vs the year before · industry median 10.7 % · above 2% of the industry

Company
Industry median

Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Assets, € thousand 2024: 284 559 € · −4.9% vs 2023

Equity, € thousand 2024: 41 787 € · −63.0% vs 2023

Employees 2024: 2 · +0.0% vs 2023 · industry median 2 · above 45% of the industry

Company
Industry median

Industry: Human health activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Financials by year
Year	Revenue, €	Net profit, €	Labour costs, €	Assets, €	Equity, €	Employees
2024	28 873	-71 167	33 308	284 559	41 787	2
2023	19 945	-85 212	31 526	299 072	112 954	2
2022	4 775	-100 122	30 462	307 383	198 166	2
2021	30 158	-57 313	30 462	328 880	185 151	2
2020	52 458	-48 043	30 462	298 971	242 464	2
2019	22 429	-24 959	24 189	166 903	118 307	2
2018	—	—	—	—	—	2
2017	—	—	—	—	—	1

Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.

Financial ratios for 2024

Net profit margin

-246.5 %

Net profit / revenue

Return on equity (ROE)

-170.3 %

Net profit / equity

Return on assets (ROA)

-25.0 %

Net profit / assets

Equity ratio

14.7 %

Equity / assets

Debt ratio

85.3 %

Liabilities / assets

Current ratio

0.19

Current assets / current liabilities

Revenue per employee

14 437 €

Revenue / average full-time employees

Labour cost per employee per month

1 388 €

Labour costs / employees / 12 months (incl. employer taxes)

Annual reports

PDFs from e-Äriregister

Annual reports
Year	Period	Filed	Report	Documents
2024	1 Jan 2024 – 31 Dec 2024	28 Jul 2025	Company’s own	e-Äriregister
2023	1 Jan 2023 – 31 Dec 2023	8 Jul 2024	Company’s own	e-Äriregister
2022	1 Jan 2022 – 31 Dec 2022	26 Sep 2023	Company’s own	e-Äriregister
2021	1 Jan 2021 – 31 Dec 2021	21 Jun 2022	Company’s own	e-Äriregister
2020	1 Jan 2020 – 31 Dec 2020	12 Oct 2021	Company’s own	e-Äriregister
2019	1 Jan 2019 – 31 Dec 2019	21 Sep 2021	Company’s own · audited	e-Äriregister

Board

Nasdaq CSD SE
Keeper of the share ledger · since 2 Jan 2018
Rakesh Pandey
Board member · since 29 Nov 2016
Reena Singh
Board member · since 21 Dec 2018

Right of representation

Any member of the management board may represent the public limited company in all transactions.

Owners

No owner information.

Beneficial owners

Rakesh Pandey
Direct ownership · since 11 Aug 2019
Reena Singh
Direct ownership · since 11 Aug 2019

Founders and other persons

Rakesh Pandey
Founder · 2 500 € · 2 Nov 2016
Audiitorbüroo Katrin Mugra OÜ
Audit firm · 28 Dec 2017
Ivo Nagel
Chairman of the supervisory board · 13 Nov 2018
Nishant Kumar
Supervisory board member · 20 Dec 2017
Kamlesh Patel
Supervisory board member · 24 Jul 2020
Omanikukonto: RAKESH PANDEY
Shareholder · 129 975 € · 28 Feb 2025
Omanikukonto: REENA SINGH
Shareholder · 33 162 € · 28 Feb 2025

shared board members, owners or beneficial owners

Activities (EMTAK)

8699Other human health activities n.e.c. Main

Rulings 20

All rulings (PDF)

Rulings
Number, date	Title	Deadline	State	Document
Ä 50042263 / M6 11 Sep 2026	Fine for not filing the report	26 Sep 2026	In force 29 Sep 2026	PDF
Ä 50042263 / M5 14 Jul 2026	Warning of a fine: annual report not filed	29 Aug 2026	In force 30 Jul 2026	PDF
Ä 50042263 / M4 15 Jul 2025	Warning of a fine: annual report not filed	27 Aug 2025	Deficiencies eliminated 29 Jul 2025	PDF
Ä 50042263 / 14 21 Feb 2025	Amendment entry		In force 21 Feb 2025	PDF
Ä 50042263 / 13 19 Sep 2024	Amendment entry		In force 19 Sep 2024	PDF
Ä 50042263 / M3 1 Aug 2024	Ruling to eliminate deficiencies	14 Sep 2024	Deficiencies eliminated 12 Sep 2024	PDF
Ä 50042263 / M2 7 Jul 2024	Warning of a fine: annual report not filed	6 Aug 2024	Deficiencies eliminated 9 Jul 2024	PDF
Ä 50042263 / 12 25 Feb 2022	Amendment entry		In force 25 Feb 2022	PDF
Ä 50042263 / 11 7 Feb 2022	Amendment entry		In force 7 Feb 2022	PDF
Ä 50042263 / 10 22 Jul 2020	Amendment entry		In force 22 Jul 2020	PDF
Ä 50042263 / 9 21 Dec 2018	Amendment entry		In force 21 Dec 2018	PDF
Ä 50042263 / 8 19 Jan 2018	Amendment entry		In force 19 Jan 2018	PDF
Ä 50042263 / 7 2 Jan 2018	Transformation entry		In force 2 Jan 2018	PDF
Ä 50042263 / 6 13 Dec 2017	Amendment entry		In force 13 Dec 2017	PDF
Ä 50042263 / 5 13 Dec 2017	Amendment entry		In force 13 Dec 2017	PDF
Ä 50042263 / M1 12 Dec 2017	Ruling to eliminate deficiencies	27 Dec 2017	Deficiencies eliminated 13 Dec 2017	PDF
Ä 50042263 / 4 12 Dec 2017	Amendment entry		In force 12 Dec 2017	PDF
Ä 50042263 / 3 28 Sep 2017	Amendment entry		In force 28 Sep 2017	PDF
Ä 50042263 / 2 21 Jan 2017	Amendment entry		In force 21 Jan 2017	PDF
Ä 50042263 29 Nov 2016	First entry		In force 29 Nov 2016	PDF

Sources: e-Äriregister and EMTA. Data updated 1 Nov 2026. Open at the source ↗ · Report an error in the data

AS Bravo Pharmaceuticals

Position in the industry Human health activities · EMTAK 86

Taxes and turnover

Financials by year

Financial ratios for 2024

Annual reports

Board

Right of representation

Owners

Beneficial owners

Founders and other persons

Related companies

Activities (EMTAK)

Rulings 20